Lieve G J Leijssen1, Anne M Dinaux1, Hiroko Kinutake1, Liliana G Bordeianou1, David L Berger2. 1. Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA, 02114, USA. 2. Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA, 02114, USA. dberger@mgh.harvard.edu.
Abstract
BACKGROUND: Although stage I colorectal cancer has an excellent prognosis after complete surgical resection, disease recurrence still occurs. This study aimed to assess prognostic risk factors in this early stage of disease. METHODS: All non-neoadjuvantly treated stage I colon (CC) and rectal (RC) patients who underwent a surgical resection between 2004 and 2015 were identified. Clinicopathological differences and long-term oncological outcomes were compared. RESULTS: CC patients (n = 433) were older and had more pre-existing comorbidities. RC patients (n = 86) were associated with more T2 tumors, venous invasion, and higher rates of 30-day morbidity. In multivariate analysis, lymphatic invasion was found to be an independent predictor for disease recurrence (OR 4.57, P = 0.010) and worse disease-free survival (HR 4.26, P = 0.012). This was particularly true for distant recurrence, with eight times higher hazard ratios when lymphatic invasion was present (HR 8.02, P < 0.001). T2 tumors were at risk, though no significant association was found (OR 3.86, P = 0.051; HR 3.61, P = 0.065, respectively). CONCLUSIONS: Lymphatic invasion was strongly associated with worse DFS, in particular distant recurrence. This subgroup of stage I patients might benefit from a more intensive follow-up and maybe should be considered for adjuvant therapy.
BACKGROUND: Although stage I colorectal cancer has an excellent prognosis after complete surgical resection, disease recurrence still occurs. This study aimed to assess prognostic risk factors in this early stage of disease. METHODS: All non-neoadjuvantly treated stage I colon (CC) and rectal (RC) patients who underwent a surgical resection between 2004 and 2015 were identified. Clinicopathological differences and long-term oncological outcomes were compared. RESULTS: CC patients (n = 433) were older and had more pre-existing comorbidities. RC patients (n = 86) were associated with more T2 tumors, venous invasion, and higher rates of 30-day morbidity. In multivariate analysis, lymphatic invasion was found to be an independent predictor for disease recurrence (OR 4.57, P = 0.010) and worse disease-free survival (HR 4.26, P = 0.012). This was particularly true for distant recurrence, with eight times higher hazard ratios when lymphatic invasion was present (HR 8.02, P < 0.001). T2 tumors were at risk, though no significant association was found (OR 3.86, P = 0.051; HR 3.61, P = 0.065, respectively). CONCLUSIONS: Lymphatic invasion was strongly associated with worse DFS, in particular distant recurrence. This subgroup of stage I patients might benefit from a more intensive follow-up and maybe should be considered for adjuvant therapy.
Authors: Brenda K Edwards; Elizabeth Ward; Betsy A Kohler; Christie Eheman; Ann G Zauber; Robert N Anderson; Ahmedin Jemal; Maria J Schymura; Iris Lansdorp-Vogelaar; Laura C Seeff; Marjolein van Ballegooijen; S Luuk Goede; Lynn A G Ries Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Nabil Wasif; Mark B Faries; Sukamal Saha; Roderick R Turner; David Wiese; Martin D McCarter; Perry Shen; Alexander Stojadinovic; Anton J Bilchik Journal: Surgery Date: 2010-02-08 Impact factor: 3.982
Authors: Satoshi Okabe; Jinru Shia; Garrett Nash; W Douglas Wong; José G Guillem; Martin R Weiser; Larissa Temple; Kenichi Sugihara; Philip B Paty Journal: J Gastrointest Surg Date: 2004-12 Impact factor: 3.452
Authors: Richard Gray; Jennifer Barnwell; Christopher McConkey; Robert K Hills; Norman S Williams; David J Kerr Journal: Lancet Date: 2007-12-15 Impact factor: 79.321
Authors: Esther K Wei; Edward Giovannucci; Kana Wu; Bernard Rosner; Charles S Fuchs; Walter C Willett; Graham A Colditz Journal: Int J Cancer Date: 2004-01-20 Impact factor: 7.396